EVVIVAX is a Biotech Company created in June 2016 as a spin off from Takis, a Biotech created by a group of scientists previously part of Merck Research Laboratories (MRL). EVVIVAX pursues the discovery and development of innovative Therapeutic Veterinary Cancer Vaccines based on a Adenoviral vector/DNA platform technology, leveraging on its strong track record in drug discovery. EVVIVAX’ frontline candidates are two therapeutic cancer vaccines for canine tumors: a) Tel-eVax, targeting Telomerase (TERT), a key molecule in Oncology. b) Erb-eVax, against HER2/neu oncogene, a well-known and validated target in Oncology. The main cancer types suitable for these immunotherapies are: Lymphomas, Breast, Osteosarcoma and Tensitional cell carcinomas. EVVIVAX business strategy for the next 5 years is: 1) to develop Tel-eVax and Erb-eVax as marketed products in USA and then in Europe; 2) license out the products to Pharma/large Biotech companies, in exchange for upfront, success-based milestones and royalty fees. Other R&D projects are under advanced pre-clinical development. EVVIVAX aims at translating scientific breakthrough achievements in Cancer Immunotherapy into marketed innovative products in Veterinary and subsequently in Human Oncology. Veterinary Oncology is an extraordinary growing market opportunity: one in every four dogs will develop cancer during its lifetime and this generally kills nearly half of pet dogs over the age ten. Cancer in canines is still predominantly treated through surgical excision, chemotherapy and radiation therapy, highly invasive procedures that can result in unpleasant side-effects. The economic benefit of EVVIVAX' products include access to a first-in class therapy (prolonged life expectation) at cost similar to current therapy and expenses reduction associated with reduced side-effects.
